Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-22T04:04:38.107Z Has data issue: false hasContentIssue false
  • English
  • Français

Chemotherapy-induced Peripheral Neuropathy Among Paediatric Oncology Patients

Published online by Cambridge University Press:  20 October 2014

M.J. Purser ,
D.L. Johnston  and
H.J. McMillan
M.J. Purser
Affiliation:
University of Ottawa, Ottawa, Ontario, Canada
D.L. Johnston
Affiliation:
University of Ottawa, Ottawa, Ontario, Canada Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
H.J. McMillan*
Affiliation:
University of Ottawa, Ottawa, Ontario, Canada Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
*
Division of Neurology, Children's Hospital of Eastern Ontario, 401 Smyth Road, Ottawa, Ontario, K1H 8L1, Canada. Email: [email protected].
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

Vinca alkaloids and platinum-containing chemotherapeutic drugs have the potential to cause chemotherapy-induced peripheral neuropathy (CIPN). This study determined the frequency of CIPN among children who were treated for acute lymphoblastic leukemia (ALL), lymphoma, brain tumour or Wilms tumour.

Procedure:

This retrospective cohort study reviewed 252 patients treated at the Children's hospital of Eastern Ontario from 2001-2011. Patients were considered to have CIPN if they developed clinical symptoms of CIPN such as limb paraesthesia, weakness and/or ataxia during chemotherapy and their treating neurologist or oncologist deemed that their symptoms were due to a peripheral cause. Patients were excluded if their treatment regime did not include chemotherapy.

Results:

The overall frequency of CIPN was 18.3% (46/252). Tumour-specific CIPN rates were: 18.9% (29/154) for ALL; 9.4% (3/32) for lymphoma; 17.9% (5/28) for Wilms tumour; and 23.7% (9/38) for brain tumour patients. Nerve conduction studies were completed for 17% of patients (all tumour types) and were abnormal in all but one patient. Among surviving CIPN patients (41/46), 93% showed no clinical deficits at their last examination, which was on average 56 months from time of diagnosis to last follow-up visit.

Conclusions:

The frequency of CIPN was less than that previously reported in adults receiving chemotherapy. Children with CIPN have a favourable outcome with most showing clinical improvement during the maintenance phase of treatment or after chemotherapy completion.

Type
Original Article
Information
Canadian Journal of Neurological Sciences , Volume 41 , Issue 4 , July 2014 , pp. 442 - 447
Copyright
Copyright © The Canadian Journal of Neurological 2014

References

1.Gilchrist, L.Chemotherapy-induced peripheral neuropathy in pediatric cancer patients. Semin Pediatr Neurol. 2012;19(1): 9–17.CrossRefGoogle ScholarPubMed
2.Aytac, S, Yetgin, S, Tavil, B.Acute and long-term neurologic complications in children with acute lymphoblastic leukemia. Turk J Pediatr. 2006;48(1):1–7.Google ScholarPubMed
3.Renbarger, JL, McCammack, KC, Rouse, CE, Hall, SD.Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer. 2008;50(4):769–71.CrossRefGoogle ScholarPubMed
4.Wolf, S, Barton, D, Kottschade, L, Grothey, A, Loprinzi, C.Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer. 2008;44(11):1507–15.CrossRefGoogle ScholarPubMed
5.Pal, PK.Clinical and electrophysiological studies in vincristine induced neuropathy. Electromyogr Clin Neurophysiol. 1999;39(6):323–30.Google ScholarPubMed
6.Egbelakin, A, Ferguson, MJ, MacGill, EA, et al. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011;56(3):361–7.CrossRefGoogle ScholarPubMed
7.Verstappen, CC, Koeppen, S, Heimans, JJ, et al. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology. 2005;64(6):1076–7.CrossRefGoogle ScholarPubMed
8.Hartman, A, van den Bos, C, Stijnen, T, Pieters, R.Decrease in motor performance in children with cancer is independent of the cumulative dose of vincristine. Cancer. 2006;106(6):1395–401.CrossRefGoogle ScholarPubMed
9.U.S. Department of Health and Human Services [homepage on the internet]. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 [updated 2010 June 14; cited 2013 Sep 17]. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdfGoogle Scholar
10.Casey, EB, Jellife, AM, Le Quesne, PM, Millett, YL.Vincristine neuropathy. Clinical and electrophysiological observations. Brain. 1973;96(1):69–86.CrossRefGoogle ScholarPubMed
11.Sghirlanzoni, A, Silvani, A, Scaioli, V, Pareyson, D, Marchesan, R, Boiardi, A.Cisplatin neuropathy in brain tumor chemotherapy. Ital J Neurol Sci. 1992;13(4):311–15.CrossRefGoogle ScholarPubMed
12.Van den Berg, HW, Desai, ZR, Wilson, R, Kennedy, G, Bridges, JM, Shanks, RG.The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemother Pharmacol. 1982;8(2):215–19.CrossRefGoogle ScholarPubMed
13.Gidding, CE, Meeuwsen-de Boer, GJ, Koopmans, P, Uges, DR, Kamps, WA, de Graaf, SS.Vincristine pharmacokinetics after repetitive dosing in children. Cancer Chemother Pharmacol. 1999;44(3):203–9.CrossRefGoogle ScholarPubMed
14.Anghelescu, DL, Faughnan, LG, Jeha, S, et al. Neuropathic pain during treatment for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011;57(7):1147–53.CrossRefGoogle ScholarPubMed
15.Reinders-Messelink, HA, Van Weerden, TW, Fock, JM, et al. Mild axonal neuropathy of children during treatment for acute lymphoblastic leukaemia. Eur J Paediatr Neurol. 2000;4(5):225–33.CrossRefGoogle ScholarPubMed
16.Chauvenet, AR, Shashi, V, Selsky, C, Morgan, E, Kurtzberg, J, Bell, B.Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol. 2003;25(4):316–20.CrossRefGoogle ScholarPubMed
17.Ness, KK, Hudson, MM, Pui, CH, et al. Neuromuscular impairments in adult survivors of childhood acute lymphoblastic leukemia: associations with physical performance and chemotherapy doses. Cancer. 2012;118(3):828–38.CrossRefGoogle ScholarPubMed
18.Lehtinen, SS, Huuskonen, UE, Harila-Saari, AH, Tolonen, U, Vainionpaa, LK, Lanning, BM.Motor nervous system impairment persists in long-term survivors of childhood acute lymphoblastic leukemia. Cancer. 2002;94(9):2466–73.CrossRefGoogle ScholarPubMed